Analysis of drug prescribing trends in treatment of rheumatoid arthritis at a tertiary care hospital, Karnataka, India


  • Dharani Devangi Ranganath Department of Pharmacology, Shimoga Institute of Medical Sciences, India
  • Deeptangshu Ganguly Department of Pharmacology, IQ city Medical College, Durgapur, West Bengal, India
  • Manjunatha Shankarappa Department of Orthopedics,KVG Medical College and Hospital, Sullia, Karnataka, India
  • Kokila Bengaluru Nagaraj Department of Pharmacology, KVG Medical College and Hospital, Sullia, Karnataka, India
  • Rajasekhar Chintha Department of Pharmacology, MM Medical College, Manipal, India



Rheumatoid arthritis, DMARDs, NSAIDs, Rational drug use


Background: This study proposes compilation, analysis of pattern, trend, rationality and frequency of use of drugs in the treatment of rheumatoid arthritis with emphasis on available treatment regimens inclusive of primary and adjunctive therapy.

Methods: The study records relevant data obtained from medical case records of patients suffering from RA above 15 years age excluding pregnancy and other arthritis, attending orthopedic OPD at KVGMC, Sullia (D.K), Karnataka, prospectively for a period of 15-18 months starting from December 2013 to June 2015.

Results: 217 patients suffering from RA were analyzed and recorded. RA was more common among the age group of 45 to 50 with female predominance (64%). RF positivity was seen in 42% cases. Out of 11 classes of drugs prescribed DMARDs (249), corticosteroids (225) and analgesics (217) played major role in treatment outcome. Non-biological DMARDs (94%) were more commonly prescribed, of which methotrexate (120) & hydroxychloroquine (128) were frequently administered. Very few patients received biological DMARDs like etanercept and infliximab. Both oral and IV preparations of corticosteroids were administered. Among the adjuvant group of drugs NSAIDs (130), opioids (53), Muscle relaxants (33), pregabalin (26), sedative/hypnotics (102) nutritional supplements (214), anti-gastric (201), antiemetic’s (13), anti-histamines (4) were prescribed accordingly. Treatment outcome was assessed at the end of 15 months and 163 patients were relieved from symptoms but no remission but there was significant association between treatment outcome and duration of treatment with DMARDs.

Conclusions: The treatment outcome and the duration of illness have significantly improved with rational use of DMARDs. Thus the study highlights and creates awareness on rational use of therapeutic agents available for treatment of RA and provides feedback to the prescriber.


Ramsay LE. Bridging the gap between clinical pharmacology and rational drug prescribing. Br J Clin Pharmacol. 1993;35:575-6.

Pavani V, Manasa C, Nalini M, Krishna RT, Parmar YM. Study of prescribing pattern of common health problems. Intern J Pharm Bio Sci. 2012;2(4):22-31.

Crockett AB. Use of prescription drugs: rising or declining? Nurs Clin North Am. 2005;40:33-49.

M de Vries TPG, Henning RH, Hogerzeil HV. Guide to good prescribing. A practical guide W.H.O. 1994.

WHO. The rational use of drugs. Report of a conference of experts, Nairobi, 25-29 November 1985. Geneva: World Health Organization; 1987.

WHO regional publications. Studies in drug utilization. European Series No. 8. Copenhagen: WHO regional publications; 1979.

Lipsky PE. Rheumatoid arthritis. In: Kasper Braunwald Fauci, Houser, Longo, Jameson, Editors. Harrison’s principle of Internal Medicine 16th edition. New York: McGraw-Hill; 2005:1968-1976.

Shini VK, Aboobacker S, Pahuja S Pharmacoeconomic study of DMARDs in the management of rheumatoid arthritis. 2010;5(3);027.

Malaviya AN, Kapoor SK, Singh RR, Kumar A, Pande I. Prevalence of rheumatoid arthritis in the adult Indian population. Rheumatol Int. 1993;13:131-4.

Chopra A, Patil J, Billampelly V, Relwani J, Tandale HS. Prevalence of Rheumatic diseases in a rural population in Western India: A WHO-ILAR COPCORD Study. J Assoc Physicians India. 2001;49:240-6.

Van der Heijde D, Klareskog L, Rodriguez-valverde V, Codreanu C, Bolosiu H, Melo-Gomes J et al. Comparison of Etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis and Rheumat. 2006;54(4):1063-74.

Goekoop-Ruiterman YPM, de Vries–Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJSM, Hazes JMW et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (The best study). Arthritis and Rheumat. 2005;52:3381-90.

Grijalva CG, Chung CP, Stein CM, Mitchel EF, Griffin MR. Changing patterns of medication use in patients with rheumatoid arthritis in a Medicaid population. J Rheumatol. 2008; 47:1061-4.

Mishra R, Sharma BL, Gupta R, Pandya S, Agarwal S. Indian rheumatology association consensus statements on the management of adults with Rheumatoid arthritis. Indian J Rheumatol. 2008;3(3):1-16.

Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR et al. American college of Rheumatology 2008 recommendations for the use of non-biologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheumat. 2008;59(6):762-84.

Felson DT, Smolen JS, Wells G. American College of rheumatology/European league against rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis. 2011;70:404-13.




How to Cite

Ranganath, D. D., Ganguly, D., Shankarappa, M., Nagaraj, K. B., & Chintha, R. (2017). Analysis of drug prescribing trends in treatment of rheumatoid arthritis at a tertiary care hospital, Karnataka, India. International Journal of Basic & Clinical Pharmacology, 5(5), 1790–1797.



Original Research Articles